A clinical isolate of neisseria gonorrhoeae with in vitro resistance to erythromycin and decreased susceptibility to azithromycin

Sexually Transmitted Diseases

Volumn 23, Issue 4, 1996, Pages 270-272

  Ehret, Josephine M ^a   Nims, Linda J ^b   Judson, Franklyn N ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b Scientific Laboratory Division   (United States)

^c DENVER PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; GONORRHEA; NEISSERIA GONORRHOEAE; NONHUMAN;

EID: 0029973117     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-199607000-00004     Document Type: Article

References (18)

1. Heilman FR, Herrell WE, Wellman WE, Geraci JE. Some laboratory and clinical observations on a new antibiotic, erythromycin (ilotycin). Proc Staff Meet Mayo Clinic 1952; 27:285-304.
2. US Public Health Service. Gonorrhea recommended treatment schedules. Ann Intern Med 1975; 82:230-233.
3. Brown ST, Pedersen AHB, Holmes KK. Comparison of erythromycin base and estolate in gonococcal urethritis. JAMA 1977; 238:1371-1373.
4. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 1988; 32:1710-1719.
5. Neu HC, Chin NX, Saha G, Labthavikul P. Comparative in vitro activity of the new oral macrolide azithromycin. Eur J Clin Microbiol Infect Dis 1988; 7:541-544.
6. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15 membered-ring macrolide with improved potency against gram negative organisms. Antimicrob Agents Chemother 1987; 31:1939-1947.
7. Lassus A. Comparative studies of azithromycin in skin and soft tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. J Antimicrob Chemother 1990; 25(suppl A):115-121.
8. Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Azithromycin in the treatment of sexually transmitted disease. J Antimicrob Chemother 1990; 25(suppl A):109-114.
9. Walsh M, Kapps EW, Quinn TC. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. Antimicrob Agents Chemother 1987; 31:811-812.
10. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. 5th ed: Approved standard. Villanova, PA: M2-A5 National Committee for Clinical Laboratory Standards, 1993.
11. Slaney L, Chubb L, Ronald A, Brunham R. In-vitro activity of azithromycin, erythromycin, ciprofloxacin, and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis. J Antimicrob Chemother 1990; 25(suppl A):1-5.
12. Guymon LF, Walstad DL, Sparling PF. Cell envelope alterations in antibiotic-sensitive and resistant strains of Neisseria gonorrhoeae. J Bacteriol 1987; 136:391-401.
13. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995; 39:577-585.
14. Eady EA, Ross JI, Cove JH. Multiple mechanisms of erythromycin resistance. J Antimicrob Chemother 1990; 26:461-471.
15. Skinner R, Cundliffe E, Schmidt FJ. Site of action of a ribosomal RNA methylase responsible for resistance to erythromycin and other antibiotics. J Biol Chem 1983; 258:12702-12706.
16. Martin DH, Mroczkowski TF, Dalu ZA for Azithromycin for Chlamydial Infections Study Group. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med 327:921-925.
17. Handsfield HH, Dalu ZA, Martin DH, et al. Multicenter trial of single-dose azithromycin vs ceftriaxone in the for treatment for uncomplicated gonorrhea. Sex Transm Dis 1994; 21:107-111.
18. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 255(suppl A):73-82.